ELN-DAVID MRD Working Party 2025 consensus update on measurable residual disease in AML, via a 2-stage Delphi: 56 recommendations (53 with ≥90% consensus), a new optimal/warning/high-risk MRD category, and NGS MRD for FLT3-ITD AML before allogeneic transplant.
Guideline
Cloos et al. 2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party